Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anastrozole, Fulvestrant and Abemaciclib for HR+, HER2- Metastatic Breast Cancer
NCT05524584Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Aug 2022
- Primary completion
- Dec 2028
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anastrozole, fulvestrant and abemaciclib in breast cancer, sponsored by University of California, Irvine. Primary endpoint: Objective Response Rate at 3 months. Started Aug 2022; status: recruiting.
02
Drugs
anastrozolefulvestrantabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05524584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524584.